TherapeuticsMD Inc (NASDAQ:TXMD)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a research note issued on Monday. They presently have a $20.00 price objective on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 231.13% from the company’s current price.
Several other analysts have also weighed in on the company. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a research report on Wednesday, May 10th. Deutsche Bank AG started coverage on TherapeuticsMD in a research report on Friday, July 21st. They issued a “buy” rating and a $10.00 target price for the company. CIBC upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 11th. Finally, Oppenheimer Holdings, Inc. upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research report on Tuesday, July 11th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. TherapeuticsMD presently has a consensus rating of “Buy” and a consensus target price of $16.14.
Shares of TherapeuticsMD (TXMD) opened at 6.04 on Monday. The company’s market capitalization is $1.23 billion. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30. The firm’s 50-day moving average price is $5.50 and its 200 day moving average price is $5.53.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The business had revenue of $4.25 million for the quarter, compared to analyst estimates of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. TherapeuticsMD’s revenue was down 3.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share. Analysts anticipate that TherapeuticsMD will post ($0.42) earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of TXMD. Bank of New York Mellon Corp increased its position in TherapeuticsMD by 12.7% in the second quarter. Bank of New York Mellon Corp now owns 22,892,018 shares of the company’s stock valued at $120,642,000 after buying an additional 2,574,120 shares in the last quarter. JPMorgan Chase & Co. increased its position in TherapeuticsMD by 14.3% in the second quarter. JPMorgan Chase & Co. now owns 15,687,509 shares of the company’s stock valued at $82,674,000 after buying an additional 1,961,656 shares in the last quarter. Stifel Financial Corp increased its position in TherapeuticsMD by 377.9% in the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after buying an additional 1,622,668 shares in the last quarter. Voya Investment Management LLC increased its position in TherapeuticsMD by 33.4% in the second quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock valued at $15,595,000 after buying an additional 741,588 shares in the last quarter. Finally, State Street Corp increased its position in TherapeuticsMD by 14.9% in the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock valued at $23,647,000 after buying an additional 583,094 shares in the last quarter.
About TherapeuticsMD
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.
